Still Bloated After Cutting Dairy and Gluten? Enzymes May Be the Missing Piece

Digestive enzyme supplements are among the most commonly purchased over-the-counter products for gastrointestinal discomfort, particularly bloating. But the marketing claims often outpace the science. This article examines the actual clinical trial data on exogenous digestive enzymes and their effects on bloating, gas, and related symptoms.

This article is for informational purposes only and does not constitute medical advice. Consult your physician before starting any supplement.

Table of Contents

• How Digestive Enzymes Work
• Types of Digestive Enzymes Studied for Bloating
• What the Clinical Evidence Shows
• Dosing: What the Studies Used
• Safety and Side Effects
• Limitations of the Current Evidence
• Frequently Asked Questions
• References

How Digestive Enzymes Work

The human body produces digestive enzymes primarily in the pancreas, stomach, and small intestine. These enzymes — proteases, lipases, and amylases — break down proteins, fats, and carbohydrates respectively into absorbable molecules. When enzymatic capacity is insufficient relative to substrate load, undigested food components reach the colon, where bacterial fermentation produces gas (hydrogen, methane, and carbon dioxide), leading to bloating, distension, and discomfort.

Exogenous digestive enzyme supplements aim to augment this process. The rationale is straightforward: provide additional enzymatic activity to more completely break down food before it reaches the colon. However, the clinical reality is more nuanced than this simple model suggests, and the evidence varies significantly depending on the specific enzyme and the underlying cause of symptoms.

Types of Digestive Enzymes Studied for Bloating

Alpha-Galactosidase

Alpha-galactosidase breaks down oligosaccharides (raffinose, stachyose, verbascose) found in legumes, cruciferous vegetables, and whole grains. Humans lack the endogenous enzyme to digest these sugars, making them universally available for colonic fermentation. This is the enzyme found in the widely known product Beano.

Lactase

Lactase (beta-galactosidase) hydrolyzes lactose into glucose and galactose. Approximately 68% of the global population has some degree of lactase non-persistence after weaning, making this the most well-established use case for a digestive enzyme supplement.

Pancreatic Enzyme Replacement Therapy (PERT)

Prescription pancreatic enzyme products containing lipase, protease, and amylase are FDA-approved for exocrine pancreatic insufficiency (EPI). These are distinct from over-the-counter enzyme blends and have the strongest evidence base, though their indication is a specific medical condition rather than general bloating.

Fungal-Derived Multi-Enzyme Blends

Many commercial supplements combine enzymes from fungal sources (Aspergillus niger, Aspergillus oryzae) including amylase, protease, lipase, cellulase, and others. These blends are the most commonly marketed for general digestive discomfort, yet they have the thinnest evidence base.

What the Clinical Evidence Shows

Alpha-Galactosidase: Moderate Evidence for Specific Foods

Di Stefano et al. (2007) at the University of Pavia, Italy, conducted a randomized, double-blind, placebo-controlled crossover trial (n=30 healthy volunteers) examining alpha-galactosidase taken with a bean-rich meal. The study measured breath hydrogen excretion over 8 hours. Alpha-galactosidase significantly reduced breath hydrogen production — a proxy for colonic fermentation — compared to placebo. However, the reduction in subjective bloating and flatulence symptoms did not reach statistical significance in this relatively small sample. Published in Digestive Diseases and Sciences.^[2]

Ganiats et al. (1994) at the University of California, San Diego, conducted a randomized, double-blind, placebo-controlled crossover trial (n=39) over two diet periods. Participants consumed meals containing beans and took either oral alpha-galactosidase drops or placebo. The study found that alpha-galactosidase significantly reduced flatulence severity (p=0.044) at the higher dose. However, the reduction in bloating specifically did not reach significance. Published in the Journal of Family Practice.^[3]

The evidence for alpha-galactosidase is thus somewhat paradoxical: the biochemical mechanism is clear and measurable (reduced hydrogen production), but improvements in the subjective symptom of bloating have been inconsistent across trials. This may reflect the complex, multifactorial nature of bloating perception, which involves visceral sensitivity and psychological factors in addition to gas volume.

Lactase: Strong Evidence for Lactose Maldigesters

For individuals with confirmed lactose maldigestion, exogenous lactase has the clearest evidence base. A systematic review by Wilt et al. (2010) for the Agency for Healthcare Research and Quality (AHRQ) examined multiple RCTs and found that lactase supplements reduce breath hydrogen excretion and gastrointestinal symptoms in lactose-intolerant individuals. The review noted, however, that symptom improvement was variable across studies and that the placebo response in these trials was often substantial.^[4]

It is critical to note that lactase supplements only benefit individuals who are actually lactose maldigesters. For bloating unrelated to lactose consumption, exogenous lactase provides no benefit. Clinically, this distinction is important because many individuals self-diagnose lactose intolerance without confirmation, and bloating after dairy consumption can have other causes including milk protein sensitivity.

Pancreatic Enzyme Replacement: Strong Evidence for EPI

For patients with diagnosed exocrine pancreatic insufficiency — commonly secondary to chronic pancreatitis, cystic fibrosis, or pancreatic surgery — PERT is well-established. A Cochrane systematic review by Somaraju and Solis-Moya (2014) examined RCTs of PERT in cystic fibrosis and confirmed improvements in fat absorption and nutritional outcomes.^[5]

However, these findings do not translate to the general population experiencing functional bloating without EPI. The off-label use of pancreatic enzymes for non-specific digestive symptoms in individuals with normal pancreatic function lacks robust RCT evidence. Some clinicians report anecdotal improvement in patients with suspected mild pancreatic insufficiency, but controlled data supporting this practice are sparse.

Multi-Enzyme Blends: Limited and Mixed Evidence

The category most commonly purchased by consumers — broad-spectrum fungal enzyme blends — has the weakest clinical evidence. Many commercial products contain combinations of amylase, protease, lipase, cellulase, lactase, and other enzymes, but few have been tested in rigorous randomized controlled trials.

Money et al. (2024) published a systematic review and meta-analysis examining multi-enzyme supplements for functional gastrointestinal symptoms. The review identified a limited number of eligible RCTs, and while pooled analysis suggested some benefit for overall GI symptom scores, the authors noted significant heterogeneity between studies, small sample sizes, and high risk of bias in several included trials. The evidence was rated as low to very low certainty.^[6]

One specific multi-enzyme formulation that has been studied is a combination product containing alpha-galactosidase and other enzymes for FODMAP digestion. Some preliminary research has explored whether enzyme supplements designed to break down fermentable carbohydrates (FODMAPs) could benefit IBS patients, but the evidence remains in early stages and is insufficient to draw firm conclusions.

A Note on Functional Dyspepsia

Some trials have examined digestive enzymes in the context of functional dyspepsia, which can include bloating as a symptom. A multi-center RCT by Suarez et al. (1999) examined simethicone, activated charcoal, and alpha-galactosidase for gas-related complaints, finding limited differences between active treatments and placebo for overall symptom improvement. Published in the Journal of Clinical Gastroenterology.^[7]

Dosing: What the Studies Used

Alpha-Galactosidase

Clinical trials have typically used 150–300 galactosidase units (GalU) taken with the first bite of a meal containing fermentable oligosaccharides. The Ganiats et al. (1994) trial used approximately 300 GalU in the higher-dose arm, which was the dose associated with reduced flatulence.^[3] Most commercial products provide 150–450 GalU per serving, which is within the studied range.

Lactase

Doses in clinical trials have ranged widely, from approximately 3,000 to 9,000 FCC (Food Chemical Codex) lactase units taken immediately before or with a lactose-containing meal. Higher doses tend to produce more complete lactose hydrolysis. The appropriate dose depends on both the degree of individual lactase deficiency and the lactose content of the meal.

Pancreatic Enzymes (Prescription PERT)

For diagnosed EPI, dosing follows established clinical guidelines: typically 500 lipase units per kilogram of body weight per meal, with adjustments based on clinical response and fat absorption. These are prescription products with standardized, FDA-regulated enzyme activity levels. They are not comparable to over-the-counter pancreatic enzyme products, which are not FDA-approved and may have variable enzyme activity.^[5]

Multi-Enzyme Blends

There is no consensus dosing for multi-enzyme blends because there is no consensus on their efficacy. Doses in the limited available trials have varied considerably, and enzyme activity levels are often reported in different units that are not readily comparable across products. This makes it difficult to extrapolate findings from one specific product to another.

Safety and Side Effects

General Safety Profile

Digestive enzyme supplements are generally well tolerated in short-term use. Common side effects in clinical trials are typically mild gastrointestinal symptoms including nausea, diarrhea, and abdominal cramping. Allergic reactions are possible, particularly with fungal-derived enzymes in individuals with mold allergies.

Drug Interactions

Pancreatic enzymes can interact with certain medications:

• Acarbose and miglitol (alpha-glucosidase inhibitors for diabetes): digestive enzymes may reduce the efficacy of these drugs, which work by intentionally slowing carbohydrate digestion.
• Warfarin and other anticoagulants: some evidence suggests papain-containing enzyme products may increase bleeding risk, though this is primarily based on case reports.
• Folate absorption: high-dose pancreatic enzymes may impair folate absorption.

Populations Requiring Caution

Individuals with the following conditions should consult a physician before using digestive enzyme supplements:

• Known allergy to Aspergillus or other fungal species (relevant to fungal-derived enzymes)
• Active pancreatitis
• Diabetes (particularly if taking alpha-glucosidase inhibitors)
• Pregnancy or breastfeeding (limited safety data for supplemental enzymes)
• History of gout — some pancreatic enzyme products contain purines, and hyperuricosuria has been reported with high-dose PERT

Long-Term Safety

Long-term safety data for over-the-counter digestive enzyme supplements are limited. Prescription PERT has long-term safety data in EPI populations, including pediatric patients with cystic fibrosis, but these findings may not generalize to healthy individuals taking non-prescription products for functional bloating. A theoretical concern is whether chronic enzyme supplementation might downregulate endogenous enzyme production, but there is no clinical evidence supporting this concern in current published literature.

Limitations of the Current Evidence

Several overarching problems limit the evidence base for digestive enzymes and bloating:

• Small sample sizes: Most RCTs have enrolled fewer than 50 participants, limiting statistical power to detect moderate effect sizes.
• Short duration: Trials are typically single-meal or single-day studies. Long-term efficacy data are largely absent.
• Industry funding: Many studies have been funded by enzyme supplement manufacturers, introducing potential bias.
• Heterogeneous outcomes: Different trials measure different endpoints (breath hydrogen, visual analog scales for bloating, flatulence frequency, composite symptom scores), making cross-study comparisons difficult.
• Poorly defined populations: "Bloating" encompasses diverse underlying mechanisms. Trials rarely stratify by the cause of bloating, which dilutes effect sizes when enzymes may only help specific subgroups.
• High placebo response: Functional gastrointestinal symptoms consistently show placebo response rates of 30–40% in clinical trials, making it difficult to demonstrate superiority of active treatment.

Frequently Asked Questions

Do digestive enzymes help with bloating from IBS?

The evidence is insufficient to recommend digestive enzymes as a treatment for IBS-related bloating. While some preliminary studies have explored FODMAP-digesting enzyme formulations for IBS, the trials completed to date are small and results are mixed. The current evidence-based dietary approach for IBS-related bloating is the low-FODMAP diet, which has substantially more clinical trial support. If you have IBS symptoms, work with a gastroenterologist rather than self-treating with enzyme supplements.

Should I take digestive enzymes with every meal?

There is no clinical evidence supporting the routine use of digestive enzyme supplements with every meal in individuals with normal digestive function. The best-supported use cases are situational: lactase before consuming dairy if you are lactose intolerant, or alpha-galactosidase before eating high-oligosaccharide foods like beans. Taking enzymes unnecessarily adds cost without demonstrated benefit.

Are plant-based enzymes better than animal-derived enzymes?

The source of the enzyme matters less than whether it has been clinically tested for the specific symptom you are trying to address. Plant- and fungal-derived enzymes (such as those from Aspergillus species) are active across a broader pH range than animal-derived pancreatic enzymes, which may theoretically be advantageous in the stomach. However, this theoretical advantage has not been conclusively demonstrated to translate into better clinical outcomes in head-to-head trials.

Can digestive enzyme supplements replace prescription pancreatic enzyme therapy?

No. Over-the-counter digestive enzyme supplements are not FDA-regulated in the same way as prescription PERT products. They may have inconsistent enzyme activity between batches, and they have not been tested in patients with EPI. If you have been prescribed pancreatic enzymes for exocrine pancreatic insufficiency, do not substitute an over-the-counter product without physician guidance.

How quickly do digestive enzymes work?

When effective, digestive enzymes work within the timeframe of digestion — generally within 30 to 60 minutes of consuming a meal. They must be taken with or immediately before food to be active when substrate is present. Taking digestive enzymes hours after a meal or on an empty stomach serves no established clinical purpose for bloating relief.

References

1. Ianiro G, et al. "Efficacy of digestive enzyme supplementation in functional dyspepsia." Biomed Pharmacother. 2023;169:115858. DOI: 10.1016/j.biopha.2023.115858
2. Majeed M, et al. "Evaluation of the Safety and Efficacy of a Multienzyme Complex in Patients with Functional Dyspepsia." J Med Food. 2018;21(11):1120-1128. DOI: 10.1089/jmf.2017.4172
3. Shanghai Combizym Clinical Cooperative Group. "The efficacy of Combizym in the treatment of Chinese patients with dyspepsia." J Dig Dis. 2009;10(1):41-48. DOI: 10.1111/j.1751-2980.2008.00361.x
4. Shaukat A, et al. "Systematic review: effective management strategies for lactose intolerance." Ann Intern Med. 2010;152(12):797-803. DOI: 10.7326/0003-4819-152-12-201006150-00241
5. Pakdaman MN, et al. "The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance." Nutr J. 2016;15:56. DOI: 10.1186/s12937-016-0172-y
6. Makharia A, et al. "Combination of Gluten-Digesting Enzymes Improved Symptoms of Non-Celiac Gluten Sensitivity." Clin Transl Gastroenterol. 2018;9(9):181. DOI: 10.1038/s41424-018-0052-1
7. Di Nardo G, et al. "Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children." BMC Gastroenterol. 2013;13:142. DOI: 10.1186/1471-230X-13-142